Eastern Cooperative Oncology Group
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eastern Cooperative Oncology Group sits in the top decile of US sponsors by registered trial count (#198 of 15,742 sponsors by registered trial count).
Eastern Cooperative Oncology Group: 141 sponsored US clinical trials, 4 recruiting.
Eastern Cooperative Oncology Group sponsors 141 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 121 completed. 37 of these trials are in Phase 3-4 (later-stage) and 90 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bladder Cancer, with 3 trials.
Top-decile sponsor footprint
Eastern Cooperative Oncology Group ranks in the top decile of sponsors by registered trial count (#198 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
121 of 131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
141 total, page 2 of 3
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
NCT00039429
Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
NCT00059982
Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00058149
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
NCT00049517
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
NCT00040807
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00041314
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
NCT00046930
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
NCT00033657
Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
NCT00028678
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
NCT00028990
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
NCT00014508
Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer
NCT00025350
Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
NCT00006390
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
NCT00010257
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer
NCT00014118
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005847
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function
NCT00005644
Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
NCT00026286
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer
NCT00006786
Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer
NCT00004860
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
NCT00005962
Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00005966
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
NCT00006385
Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer
NCT00006004
flt3L in Treating Patients With Acute Myeloid Leukemia
NCT00006223
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00006008
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00005609
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia
NCT00003764
Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer
NCT00005045
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
NCT00004223
Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
NCT00004225
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
NCT00003907
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
NCT00004125
Diagnostic Study of Patients With Stage I Testicular Cancer
NCT00003800
Methylphenidate in Treating Patients With Melanoma
NCT00003266
Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer
NCT00003206
PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer
NCT00003871
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
NCT00003910
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
NCT00003864
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
NCT00003810
Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia
NCT00003808
Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
NCT00003809
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
NCT00003388
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
NCT00003389
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
NCT00003615
Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer
NCT00003309
Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00003881
Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer
NCT00003592
Combination Chemotherapy in Treating Patients With Bladder Cancer
NCT00003701
Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin
NCT00003444
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 87 |
| Phase 3 | 37 |
Therapeutic Areas
What is open in the Eastern Cooperative Oncology Group pipeline
4 recruiting of 141 indexed (3% open); 121 completed (86%).
Phase mix: 37 late (III/IV) vs 90 early (I/II) (early-phase heavy).
Top condition: Bladder Cancer (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eastern Cooperative Oncology Group: open-pipeline peers nationwide
Peers matched on 141 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Eastern Cooperative Oncology Group sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 141 trials (± recruiting share)
- Case Western Reserve University · 141 trials · 16% recruiting
- Purdue University · 141 trials · 10% recruiting
- Johnson & Johnson Vision Care · 142 trials · 1% recruiting
- Mclean Hospital · 140 trials · 19% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Merz North America · 3% recruiting · 35 trials
- VIVUS · 3% recruiting · 35 trials
- Enanta Pharmaceuticals · 3% recruiting · 36 trials
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 3% recruiting · 138 trials
Related
What to do with this Eastern Cooperative Oncology Group page
141 registered trials is a research-attention snapshot, not an endorsement of Eastern Cooperative Oncology Group or any single study.
- 4 of Eastern Cooperative Oncology Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Bladder Cancer is the condition Eastern Cooperative Oncology Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bladder Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eastern Cooperative Oncology Group pipeline card: 141 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.